CoChat

A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes.

Yoshida, Yilin, Cheng, Xi, Shao, Hui, Fonseca, Vivian A., Shi, Lizheng · 2020 · Current Diabetes Reports

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Purpose of review Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved class of drugs (since 2012) for type 2 diabetes mellitus (T2DM), but their economic merits have yet been fully confirmed. The objective of this review was to evaluate the most updated evidence that examined the cost-effectiveness of SGLT2i for T2DM.Recent findings We systematically searched Medline (PubMed), EMBASE, and Web of Science for eligible articles from January 1, 2011, to October 31, 2019, using combinations of search words. A supplementary search using reference lists of eligible articles and other review articles was also performed. A multistage screening process was carried out with duplicates removal, abstract screening, and full-text reading to confirm eligibility. Two reviewers independently screened the eligible articles and assessed reporting quality using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. A total of 24 studies were included in the final review. All studies showed good quality according to the CHEERS checklist (scored 21-24). Seven studies compared SGLT2i vs. dipeptidyl peptidase-4 inhibitors (DPP-4i), 3 studies compared SGLT2i vs. sulfonylureas (SU), 3 compared SGLT2i vs. glucagon-like peptide-1 receptor agonist (GLP-1 RA), 2 compared SGLT2i vs. SGLT2i, 3 compared SGLT2i vs. other antidiabetic therapies including thiazolidinediones (TZD), alpha-glucosidase inhibitors (AGI) or insulin, and 5 compared SGLT2i vs. standard care/metformin. Most studies concluded SGLT2i was cost-effective relative to its comparator except GLP-1 RA, where two studies suggested GLP-1 RA was the favorable treatment option relative to SGLT2i. The literature demonstrated that SGLT2i may be cost-effective compared to many antidiabetic therapies including DPP-4i, SU, TZD, AGI, insulin, and standard care .

Overview

Integrity signals

Registry

Crossref · 10.1007/s11892-020-1292-5

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 46 references

Cited by

See all 39

Metadata

Authors
Yoshida, Y., Cheng, X., Shao, H., Fonseca, V. A., & Shi, L.
Affiliations
  • Tulane University (US)
  • University of South Carolina (US)
  • University of Florida (US)
Corresponding author
Shi, Lizheng
Venue
Current Diabetes Reports
Published
2020-03-12
Volume
20
Issue
4
Pages
12-12
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
OpenAlex
W3012131422
Cited by
39
References
46
Citations by year
2026: 5 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 1
FWCI
0.95
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Diabetes Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
SGLT2 inhibitors, type 2 diabetes, cost-effectiveness, economic evaluation, DPP-4 inhibitors, sulfonylureas, GLP-1 receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, insulin, metformin
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. https://app.cochat.ai/papers/10.1007/s11892-020-1292-5
The paper
Yoshida, Y., Cheng, X., Shao, H., Fonseca, V. A., & Shi, L. (2020). A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Current Diabetes Reports. https://doi.org/10.1007/s11892-020-1292-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.